FDA Approves New Formulation of the #PSMA PET Agent Pylarify
www.diagnosticimaging.com/view/fda-app...
#radiology #RadRes #ProstateCancer
Latest posts tagged with #PSMA on Bluesky
FDA Approves New Formulation of the #PSMA PET Agent Pylarify
www.diagnosticimaging.com/view/fda-app...
#radiology #RadRes #ProstateCancer
Check out our latest findings on #Metformin effects on renal function in #mCRPC during #PSMA radiopharmaceutical therapy @ascocancer.bsky.social #GU26
ascopubs.org/doi/abs/10.1...
@ascopost.bsky.social
Still in the Dark…
#PCWG4 launched #GU26 w/aspirational reliance on #PSMA imaging for drug development
But we will have to acknowledge that #PSMA targeted therapy will likely impact the sensitivity of #PSMA imaging
#PSMAdark
@ascocancer.bsky.social
@melissaabel20 et al
rdcu.be/eKNQe
The #NCI past meets the present #GU26 @ascocancer.bsky.social
Dr. Melissa Abel discusses emerging #PSMA tumor volume data with Dr. Harpreet Singh
The emerging data is from a follow-up trial based on a trial Dr. Singh worked on during her time at the NCi
More data on PSA
Almost none on PSMA
So I would not used PSMA “response” since all that really is telling us about fundamentally is #PSMA expression.
#ProstateCancer @ascocancer.bsky.social #GU26
Still in the Dark…
#PCWG4 launched @ascocancer.bsky.social #GU26 w/aspirational reliance on #PSMA imaging for drug development
But we will have to acknowledge that #PSMA targeted therapy will likely impact the sensitivity of #PSMA imaging
#PSMAdark
@melissaabel20 et al
rdcu.be/eKNQe
Poster A14
#GU26
@ascocancer.bsky.social
One key bit of data missing in the context of #PSMA+ #BCR #ProstateCancer management in the wake of the #EMBARK data is how does #PSA Doubling Time interface w/ #PSMA Pet findings.
Dr. Melissa Abel from #NCI will share this data today
PosterA4 #GU26
@ascocancer.bsky.social
#BCR #ProstateCancer study @thenci
🩻PSMA➡️ 3 mos Enza💊➡️PSMA🩻
PSA control=days below baseline=clinical benefit🔵
PSA⬇️88-100%🟠
#PSMA Tumor Volume🟢
🚨PSMA-TV⬇️s/p Enza does NOT predict benefit
These data in PSMA responders raise❓for adaptive designs
🔜 #GU26 @ascocancer.bsky.social
“These findings… highlight the need for larger… studies to validate the prognostic value of PSMA-guided disease stratification & ensure its generalizability across diverse populations.”
Agree!! Need more #PSMA data less presumption in #ProstateCancer
岡山大学、前立腺がん治療に新しい光をもたらすPSMAルテチウム療法を導入 #岡山大学 #前立腺がん #PSMA
岡山大学が新たに導入したPSMAルテチウム療法は、従来の治療法に効果が見られなかった前立腺がん患者に希望をもたらします。最新の放射線治療技術で、地域の医療を支えます。
With #GU26 approaching one key bit of data missing in the context of #PSMA+ #BCR #ProstateCancer management in the wake of the #EMBARK data is how does #PSA Doubling Time interface w/ #PSMA Pet findings.
Dr. Melissa Abel @ the NCI will share this data @ #GU26 @ascocancer.bsky.social
New review highlights how PSMA‑targeted radioligand therapy, including 177Lu‑PSMA‑617 and emerging isotopes like 225Ac/161Tb, is reshaping advanced prostate cancer care. Combination strategies and precision dosimetry point to a rapidly evolving future.
🔗 buff.ly/WKhPij0
#ProstateCancer #RLT #PSMA
New research from Dr. Samir Zaidi with Dr. Michael Morris @mskcancercenter.bsky.social shows #PSMA expression can vary in #mCRPC, even in tumors that appear PSMA+ on imaging. Combining PSMA scans with blood-based biomarkers may help inform treatment decision–making.
aacrjournals.org/clincancerre...
FDA Clears #AI Software for #PSMA PET/CT and SPECT/CT Tumor Burden Analysis
www.diagnosticimaging.com/view/fda-ai-...
#radiology #RadRes
Study Suggests Merits of #PSMA PET/MRI for Detecting HCC in LI-RADS 3 Cases
www.diagnosticimaging.com/view/study-p...
#radiology #RadRes
Can #PSMA PET Parameters Help Predict Toxicity and Outcomes in Patients Treated for mCRPC?
www.diagnosticimaging.com/view/psma-pe...
#radiology #RadRes #ProstateCancer
Feasibility study of 225Ac-PSMA-CY313 dosimetry in mCRPC patients using SPECT.
Gu, Huajian et al.
Paper
Details
#PSMA #225Ac #Dosimetry
Daily reminder:
#PSMA doesn't show everything...
100 pts w/#BCR #ProstateCancer s/p previous PSMA radioguided surgery
▶️median PSA=0.9
‼️91% recur@ median 11.4mos
‼️47%w/ distant recurrence beyond pelvis
Important for pts to be aware of these data
jnm.snmjournals.org/content/66/1...
Can an Integrated Approach with #PSMA PET/CT and Prostate #MRI Enhance Detection of Extraprostatic Extension?
www.diagnosticimaging.com/view/integra...
#radiology #RadRes #RSNA25
Should #PSMA PET/CT Supplant #MRI For Staging of Patients with High-Risk PCa?
www.diagnosticimaging.com/view/should-...
#radiology #RadRes #RSNA25
🌊Here's a quick recap of what happened at the 2025 annual meeting of the International Commission for the Conservation of the Atlantic #Tunas ( #ICCAT ) which wrapped up earlier in the week. Bonus points for spotting the glitch in the #matrix 🫣
#IUUfishing #IUU #PSMA
New #PSMA PET/CT-Based #AIart Tool May Facilitate Monitoring of Treatment Response in Patients with PCa
www.diagnosticimaging.com/view/new-psm...
#radiology #RadRes #ProstateCancer
A patient with a prostate-specific membrane antigen (#PSMA)-positive PET/CT findings was ultimately diagnosed with #SystemicMastocytosis (SM) rather than metastatic #ProstateCancer, according to a recently published case report.
Read here: https://bit.ly/43tRgJf
#RareDisease #MedSky
Clinical and #Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive #ProstateCancer @EUplatinum
#PSMA
www.sciencedirect.com/science/arti...
Not all PSMA+ BCR is oligo mets and PSMA+ BCR is very different than mCSPC. Imaging platform matters for patients and outcomes when defining “oligomets” but trials are very inconsistent on this key issue. Ref for image: https://ascopubs.org/doi/10.1200/JCO-25-01693
Lots of ❓s in defining benefits of “#oligomet” or “#MDT” therapy in #ProstateCancer
❓ADT+/-ARPI? How long?
❓PFS vs Eugonadal PFS?
❓how many mets? Where?
🔑❓what imaging 🩻❓
#PSMA mets🚫🟰CT/Bone scan mets
shorturl.at/n3JwU
Std of Care? Or just something we can do?
Study: #PSMA PET/CT Changed Treatment Plans for Over a Third of Men with #ProstateCancer
www.diagnosticimaging.com/view/study-p...
#radiology #RadRes
Nine Takeaways from New Review of #PSMA PET/CT and Whole-Body #MRI for Advanced #ProstateCancer www.diagnosticimaging.com/view/nine-ta...
#radiology #RadRes
We don’t need to fear the Dark in #ProstateCancer
But we will have to acknowledge that #PSMA targeted therapy will likely impact the sensitivity of #PSMA imaging
This likely impacts the desire to use PSMA in restating (still unclear how to do that) & drug development #PSMAdark
New #PSMA PET Research Shows Merits of Pluvicto in Metastatic Hormone-Sensitive #ProstateCancer (mHSPC)
www.diagnosticimaging.com/view/psma-pe...
#radiology #RadRes #ESMO25
Lots @ #ESMO25 re: #BCR #ProstateCancer but over-treatment of this indolent disease remains an important issue
How does #PSMA imaging factor in? See poster #2393P presented by @HelenMoonMD Saturday
+PSMA findings in BCR pts shouldn’t be the reason to treat as rPD is rare @1yr